Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.

Finally, we observed a nonsignificant trend of NF-κB pathway-activating mutagenic events in patients with TNFRSF17 biallelic loss or mutations, with three out of the six patients harboring clonal TRAF3 or CYLD or MAP3K14 biallelic deletion or SNVs (Supplementary Fig. 7 ).

also in 5,406 other papers